Tsveta Milanova
CCO
Equibles does not estimate personal net worth.
About Tsveta Milanova
Tsveta Milanova has spoken on 3 earnings calls across 1 company, most recently for Agios Pharmaceuticals, Inc. on April 29, 2026. The companies whose calls Tsveta Milanova spoke on are classified in the Healthcare sector.
Tsveta Milanova on recent calls
“So, as I said, we are very excited with the early launch and the progress we've made.”
“In the third quarter, we delivered $12.9 million in PYRUKYND net revenues, up 3% sequentially, once again reflecting strong execution by our commercial team. To date, 262 patients have completed prescription enrollment forms, including 14 in the third quarter, representing a 6% increase sequentially.”
“Our commercial organization is laser-focused on executing a comprehensive strategy that addresses each phase of the patient journey from disease awareness to reimbursement, adherence, and persistency.”